Literature DB >> 34170

[Pharmacokinetics of bufuralol in man].

L Balant, R J Francis, J M Tschopp, D Tinguely, J Estreicher, J Fabre.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 34170

Source DB:  PubMed          Journal:  Pharm Acta Helv        ISSN： 0031-6865


× No keyword cloud information.
  6 in total

1.  Relationship between pharmacokinetic and pharmacodynamic behaviour of bufuralol and its metabolite Ro 3-7410 in hypertensive patients.

Authors:  M Eckert; G Cocco; C Strozzi; P Heizmann; C Sfrisi
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers.

Authors:  P Dayer; A Kubli; A Kupfer; F Courvoisier; L Balant; J Fabre
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

3.  Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.

Authors:  P Dayer; L Balant; A Kupfer; R Striberni; T Leemann
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  The genetic control of bufuralol metabolism in man.

Authors:  P Dayer; L Balant; F Courvoisier; A Kupfer; A Kubli; A Gorgia; J Fabre
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

5.  Influence of renal failure on the hepatic clearance of bufuralol in man.

Authors:  L Balant; R J Francis; T N Tozer; A Marmy; J M Tschopp; J Fabre
Journal:  J Pharmacokinet Biopharm       Date:  1980-10

6.  Kinetics and metabolism of (+)-, (-)- and (+/-)-bufuralol.

Authors:  R J Francis; P B East; J Larman
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.